Terbufibrol
(Synonyms: 特丁贝罗) 目录号 : GC31457
Terbufibrol在正常和高胆固醇血症雄性大鼠中，高效降低血清总胆固醇(TC)水平。
Cas No.:56488-59-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
Terbufibrol (20-200 mg/kg) is active in lowering serum TC in animals on all 3 diets, but the extent of cholesterol reduction varies in the order cholesterol (HC)>high protein and fat diet (HPF)>N (max. reductions: 154, 80, and 70%, respectively). Clofibrate (200 mg/kg) decreases TC by a maximum of 28% with the HPF-diet and 13% with the N-diet but is inactive with the HC-diet. Cholestyramine (400 mg/kg/day) is inactive in HPF-fed animals but reduces TC in HC-fed animals by 45%. With the HPF-diet nicotinic acid (200 mg/kg) is inactive. Terbufibrol lowers HDL, HDL-TC, LDL, LDL-TC and LDL-TC/PL in animals fed HPF-diet. A greater decrease of LDL-TC occurres with increasing dose. The main effect of Clofibrate (200 mg/kg) is to reduce HDL and HDL-TC and to increase LDL[1].
[1]. Howard AN, et al. The hypocholesterolemic effect of terbufibrol and other drugs in normal and hypercholesterolemic baboons. Atherosclerosis. 1979 Apr;32(4):367-80.
Animal experiment: | Baboon[1] Eighteen baboons (9 male, 9 female) are given the N-diet throughout, divided into 3 groups of 6 animals, and treated with Terbufibrol for 8 weeks, as follows: Group 1: control; Group 2: 50 mg/kg per day; Group 3: 200 mg/kg per day. |
References: [1]. Howard AN, et al. The hypocholesterolemic effect of terbufibrol and other drugs in normal and hypercholesterolemic baboons. Atherosclerosis. 1979 Apr;32(4):367-80. | |
| Cas No. | 56488-59-6 | SDF | |
| 别名 | 特丁贝罗 | ||
| Canonical SMILES | O=C(O)C1=CC=C(OCC(O)COC2=CC=C(C(C)(C)C)C=C2)C=C1 | ||
| 分子式 | C20H24O5 | 分子量 | 344.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9036 mL | 14.518 mL | 29.036 mL |
| 5 mM | 0.5807 mL | 2.9036 mL | 5.8072 mL |
| 10 mM | 0.2904 mL | 1.4518 mL | 2.9036 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet